Septerna has secured $150 million in a series B fundraise, money that will go toward two newly unveiled programs including moving its first G-protein-coupled receptor (GPCR) drug into the clinic.The San Francisco-based biotech roped in nine new investors for the series B, CEO and co-founder Jeffrey Finer, M.D., Ph.D., told Fierce Biotech in an interview. […]
